Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 15/20 | 0.71 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1513880 | 1.00 | GRM4 (0.71) | GRM4GRM1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1513986 | 0.99 | GRM4 (0.69) | GRM4GRM1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1513890 | 0.97 | GRM4 (0.67) | GRM4GRM1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12700797 | 0.90 | GRM4 (0.58) | GRM4GRM1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12695716 | 0.89 | GRM4 (0.57) | GRM4GRM1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12543278 | 0.87 | GRM4 (0.61) | GRM4GRM1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1513936 | 0.87 | GRM4 (0.70) | GRM4GRM1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1514071 | 0.87 | GRM4 (0.54) | GRM4GRM1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1898799 | 0.83 | GRM4 (1.00) | GRM4GRM1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1899539 | 0.83 | GRM4 (0.79) | GRM4GRM1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779157-B2 | MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779157-B2 | MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779157-B2 | MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120245153-A1 | MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245153-A1 | MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245153-A1 | MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2012-09-27 | — | — | US | disclosed |
| EP-2473055-A1 | MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | Vanderbilt University (US) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011029104-A1 | MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011029104-A1 | MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245153-A1 | MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRM4, GRIK4, GRM2 | GRM4 1/4885GRM1 4/4885CYP1A2 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.